Genelux Corporation

Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, April 1, 2024
Research, Lung cancer, Medical school, Shanghai Jiao Tong University, Carcinoma, Fast track (FDA), Form, Patient, G&A, School, IPO, Hope, Security (finance), Guggenheim Partners, Investment, Platinum, Interim, Genelux Corporation, FDA, Pharmaceutical industry

WESTLAKE VILLAGE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, reported fourth quarter and full year 2023 financial results and business updates.

Key Points: 
  • – $23.2 million in cash, cash equivalents and short-term investments –
    WESTLAKE VILLAGE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, reported fourth quarter and full year 2023 financial results and business updates.
  • Currently, 21 sites have been activated to enroll patients with additional sites identified and in various stages of activation ( NCT05281471 ).
  • Genelux and our partner Newsoara co-sponsor the trial, which is being conducted by Newsoara in greater China.
  • Cash, cash equivalents and short-term investments were $23.2 million as of December 31, 2023 compared to $0.4 million on December 31, 2022.

Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer

Retrieved on: 
Monday, November 27, 2023
Platinum, Priority review, Ovarian cancer, FDA, Genelux Corporation, Patient, Safety, Fast Track, Pharmaceutical industry

WESTLAKE VILLAGE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation for the development program of Olvi-Vec (olvimulogene nanivacirepvec) for the treatment of patients with platinum resistant/refractory ovarian cancer.

Key Points: 
  • WESTLAKE VILLAGE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation for the development program of Olvi-Vec (olvimulogene nanivacirepvec) for the treatment of patients with platinum resistant/refractory ovarian cancer.
  • “The Fast Track designation granted for Olvi-Vec underscores its potential to address unmet medical needs in ovarian cancer, a significant recognition as we continue to enroll our Phase 3 OnPrime study,” said Thomas Zindrick , President, Chairman and CEO of Genelux.
  • The purpose of Fast Track designation is to facilitate the development and hasten the review process of drugs aimed at treating serious and life-threatening conditions, ensuring that an approved product can swiftly enter the market.
  • Notable aspects of Fast Track designation encompass regular engagements with the FDA review team, and, if specific criteria are satisfied, potential eligibility for Priority Review and Rolling Review.

Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates

Retrieved on: 
Tuesday, November 14, 2023
Accounting, Safety, D, Platinum, Carcinoma, Sonifi Solutions, CFO, Patient, Investment, Research, IPO, Financial management, Hand, Amgen, Pharmaceutical industry, Genelux Corporation

WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) --  Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter of 2023 and provided general business updates.

Key Points: 
  • WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter of 2023 and provided general business updates.
  • R&D Expenses: Research and development expenses were $2.8 million for the third quarter of 2023, as compared to $2.4 million for the third quarter of 2022.
  • G&A Expenses: General and administrative expenses were $2.5 million for the third quarter of 2023, as compared to $2.2 million for the third quarter of 2022.
  • Net Loss: Net loss was $5.3 million for the third quarter of 2023, as compared to net income of $4.9 million for the third quarter of 2022.

Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment

Retrieved on: 
Wednesday, October 11, 2023
Acromegaly, MBA, NYSE, Acquisition, FOLFIRINOX, Pancreas, PK, Carcinoid syndrome, Safety, Survival, Therapy, Oncolytics Biotech, JV, NEO, ADC, Research, JD, Lung cancer, Patient, Ovarian cancer, CR, PFE, Genelux Corporation, Survival rate, TSX, VC, Public, Medicine, Cancer, FDA, Melanoma, Immunotherapy, Pancreatic Cancer Action Network, FTD, Diagnosis, Glomus tumor, News, Death, ORR, PDAC, IND, ONC, CAD, Growth, Pancreatic cancer, Pharmaceutical industry, Medical imaging, Seagen, Pfizer, Pelareorep

VANCOUVER, British Columbia, Oct. 11, 2023 /PRNewswire/ -- USA News Group - Researchers are becoming increasingly concerned with the rates of cancer on the rise among people under 50. A recent study found a nearly 80% global increase in the number of under-50s getting diagnosed with cancer from 1990 to 2019. And among the most worrying rise is in pancreatic cancer, which comes with extremely low survival rates. However, with strategies such as the "Cancer Moonshot," a $200M boost from a newly formed VC firm, and sustained efforts from the Pancreatic Cancer Action Network (PanCAN), a leading pancreatic cancer organization, which this year noted the 5-year survival rate is approximately 12%. Many new developments are currently underway from biotech firms searching for new treatments and methods of diagnosis, including those from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Genelux Corporation (NASDAQ: GNLX), Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX), Pfizer Inc. (NYSE: PFE) and Seagen Inc. (NASDAQ: SGEN).

Key Points: 
  • And among the most worrying rise is in pancreatic cancer, which comes with extremely low survival rates.
  • "By teaming up with PanCAN, we believe we may be able to expedite development and provide pancreatic cancer patients with a bespoke immunotherapeutic treatment option."
  • Further survival follow up is required to inform our next steps in pancreatic cancer," said Roger Dansey, M.D., Chief Medical Officer at Seagen.
  • "We are continuing to advance the ongoing phase 2 trial of SEA-CD40 in melanoma and in non-small cell lung cancer."

Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment

Retrieved on: 
Wednesday, October 11, 2023
Acromegaly, MBA, NYSE, Acquisition, FOLFIRINOX, Pancreas, PK, Carcinoid syndrome, Safety, Survival, Therapy, Oncolytics Biotech, JV, NEO, ADC, Research, JD, Lung cancer, Patient, Ovarian cancer, CR, PFE, Genelux Corporation, Survival rate, TSX, VC, Public, Medicine, Cancer, FDA, Melanoma, Immunotherapy, Pancreatic Cancer Action Network, FTD, Diagnosis, Glomus tumor, News, Death, ORR, PDAC, IND, ONC, CAD, Growth, Pancreatic cancer, Pharmaceutical industry, Medical imaging, Seagen, Pfizer, Pelareorep

VANCOUVER, British Columbia, Oct. 11, 2023 /PRNewswire/ -- USA News Group - Researchers are becoming increasingly concerned with the rates of cancer on the rise among people under 50. A recent study found a nearly 80% global increase in the number of under-50s getting diagnosed with cancer from 1990 to 2019. And among the most worrying rise is in pancreatic cancer, which comes with extremely low survival rates. However, with strategies such as the "Cancer Moonshot," a $200M boost from a newly formed VC firm, and sustained efforts from the Pancreatic Cancer Action Network (PanCAN), a leading pancreatic cancer organization, which this year noted the 5-year survival rate is approximately 12%. Many new developments are currently underway from biotech firms searching for new treatments and methods of diagnosis, including those from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Genelux Corporation (NASDAQ: GNLX), Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX), Pfizer Inc. (NYSE: PFE) and Seagen Inc. (NASDAQ: SGEN).

Key Points: 
  • And among the most worrying rise is in pancreatic cancer, which comes with extremely low survival rates.
  • "By teaming up with PanCAN, we believe we may be able to expedite development and provide pancreatic cancer patients with a bespoke immunotherapeutic treatment option."
  • Further survival follow up is required to inform our next steps in pancreatic cancer," said Roger Dansey, M.D., Chief Medical Officer at Seagen.
  • "We are continuing to advance the ongoing phase 2 trial of SEA-CD40 in melanoma and in non-small cell lung cancer."

Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, September 14, 2023
Genelux Corporation, Employment, Pharmaceutical industry, Property management

The Board approved the awards as an inducement material to such new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The Board approved the awards as an inducement material to such new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Each stock option has an exercise price per share equal to $22.40 per share, the Company’s closing sales price on September 11, 2023.
  • Each stock option will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with the Company through the applicable vesting dates.
  • The awards are subject to the terms and conditions of the Company’s 2023 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.

Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference

Retrieved on: 
Thursday, September 7, 2023
Genelux Corporation, Conference, Cryptocurrency

WESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, Chairman and CEO, will present a corporate overview with institutional investors during the H.C. Wainwright 25th Annual Global Investment Conference held the week of September 11th, 2023.

Key Points: 
  • WESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, Chairman and CEO, will present a corporate overview with institutional investors during the H.C. Wainwright 25th Annual Global Investment Conference held the week of September 11th, 2023.
  • The Company will also attend virtual one-on-one meetings during the conference.
  • Institutional investors interested in arranging a meeting with Genelux management can register to attend the conference virtually or contact [email protected].

Genelux Corporation Announces New Chief Financial Officer

Retrieved on: 
Monday, August 28, 2023
CFO, Amgen, IPO, Knowledge, Accounting, Financial management, Sonifi Solutions, Management, Genelux Corporation, Finance

WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the company as Chief Financial Officer, effective August 28, 2023.

Key Points: 
  • WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the company as Chief Financial Officer, effective August 28, 2023.
  • "I am excited to welcome Lourie to Genelux as our new Chief Financial Officer," said Thomas Zindrick , President, Chairman and CEO of Genelux.
  • Ms. Zak will join Genelux with an extensive background in CFO roles, including Guitar Center Brands, Sonifi Solutions, and PBS Biotech.
  • Doug Samuelson, who played an important role as the Company’s Chief Financial Officer during its IPO earlier this year, is set to resume his position as Vice President of Finance.

Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates

Retrieved on: 
Monday, August 14, 2023
IPO, Senior, Investment, Head, JAMA, Clinical trial, Drug, Article, MS, American Medical Association, Journal, Russell, Patient, Patent, Regulatory affairs, Research, Pharmaceutical Development and Technology, Safety, D, Pharmaceutical industry, Genelux Corporation, Q2, NSCLC, Quality, MD

WESTLAKE VILLAGE, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2023 and provided general business updates.

Key Points: 
  • - $51 Million raised after closing of two private placements in Q2, totaling $65 million raised in the first half of 2023 -
    WESTLAKE VILLAGE, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2023 and provided general business updates.
  • R&D Expenses: Research and development expenses were $2.9 million for the second quarter of 2023, as compared to $1.8 million for the second quarter of 2022.
  • G&A Expenses: General and administrative expenses were $2.5 million for the second quarter of 2023, as compared to $1.0 million for the second quarter of 2022.
  • Net Loss: Net loss was $5.8 million for the second quarter of 2023, as compared to a net loss of $2.8 million for the second quarter of 2022.

Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2023

Retrieved on: 
Wednesday, August 2, 2023
Genelux Corporation, Doctor of Philosophy, Conference, Pharmaceutical industry, Communications satellite

WESTLAKE VILLAGE, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman, will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat at BTIG’s Virtual Biotechnology Conference 2023.

Key Points: 
  • WESTLAKE VILLAGE, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman, will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat at BTIG’s Virtual Biotechnology Conference 2023.
  • The conversation with Kaveri Pohlman, PhD, Director and BTIG Biotechnology Analyst, is scheduled to begin at 4:00 p.m.
  • ET on Tuesday, August 8, 2023.